Memantine Ohre Pharma

Memantine Hydrochloride, the active ingredient in Memantine Ohre Pharma, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. The medication works by modulating glutamatergic neurotransmission, helping to reduce excitotoxic neuronal damage associated with disease progression.

GNH USA supplies Memantine Ohre Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, with a focus on quality assurance and regulatory compliance.

Memantine, an NMDA receptor antagonist, is employed in the therapeutic approach to neurodegenerative conditions, with its principal clinical application being the treatment of Alzheimer’s disease, where it targets glutamate‑mediated excitotoxicity to support neuronal function.

Alzheimer’s disease (moderate to severe): improves cognition, functional abilities, and global clinical status in patients with symptomatic disease. Behavioral symptoms in Alzheimer’s disease: may reduce agitation, aggression, and caregiver burden. Dementia due to Alzheimer’s disease: supports activities of daily living and slows functional decline.

Memantine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: occasional disorientation.

Serious or Rare Side Effects: - Severe skin rash (e.g., Stevens‑Johnson syndrome): requires immediate medical attention. - Seizures: rare but potentially life‑threatening. - Hallucinations or psychosis: may occur in susceptible individuals. - Cardiac arrhythmia: irregular heart rhythm requiring evaluation.

When prescribing Memantine, clinicians should consider several safety aspects. - Renal impairment: assess renal function and adjust dose if necessary. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: monitor closely for increased seizure activity. - Concurrent use with other NMDA antagonists: avoid additive neurotoxicity. - Psychiatric disorders: observe for worsening of symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Memantine can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism may enhance CNS effects. - Other NMDA antagonists: heightened central nervous system depression.

Moderate Interactions (Monitor Closely): - Anticholinergics: may reduce Memantine efficacy. - CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation and respiratory depression. - Diuretics (e.g., furosemide): may alter plasma concentrations of Memantine.